AMAG Pharmaceuticals has provided a safety update on Feraheme (ferumoxytol injection) indicating that serious adverse events have been reported at a rate consistent with that contained in the Prescribing Information. Of the estimated 35,000 patient exposures to date, 40 serious adverse events have been reported, an approximate rate of 0.1%. No mortality signal has been observed. A single reported death occurred in a patient two days post-Feraheme treatment, which AMAG does not believe was the result of Feraheme.
Feraheme is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
For more information call (617) 498-3300 or visit www.amagpharma.com.